Autologous Fat Grafting Market to Witness Healthy Growth; Developed Countries to

Posted by Arslan on August 26th, 2019

According to a new study of Fact.MR, the autologous fat grafting market reached ~US$ 320 Mn in 2018, and is estimated to record ~14% Y-o-Y in 2019.   Autologous fat grafting continues to gain popularity as an effective solution for various volume filling applications, despite lack of standardized guidelines for harvesting, processing and implementation. Leading players in the autologous fat grafting market are putting efforts for discovering ideal methodology for the process, considering patient-related aspects while formulating strategies. 

The study opines that autologous fat grafting will be the next frontier in the aesthetic medicine landscape, gaining widespread acceptance as an efficient method to satisfy patient requirement for larger volume loss cost-effectively. Comprehensive solutions have been introduced by stakeholders in the autologous fat grafting market, which enable achieving consistency in the high fat viability, even as maximizing the longevity of fat transfer results. 

Autologous Fat Grafting Market in Numbers

  • Demand for autologous fat grafting procedures accounted for the revenues worth US$ 317 Mn, in 2018. Continued preference for the use of non-invasive aesthetic techniques in skin rejuvenation is primarily favoring the growth of autologous fat grafting market.
  • ~14% CAGR has been projected for the autologous fat grafting market over 2019-2029, which is prominently estimated to be driven by the increasing social acceptance of aesthetic cosmetic procedures.
  • North America is anticipated to remain the leading market for autologous fat grafting during the forecast period.
  • Latin America’s market for autologous fat grafting is anticipated to witness ~17% CAGR through 2029..

Request Free Sample Report Here:

Key Challenges Facing Autologous Fat Grafting Market

  • The potential risk of the injected fat getting reabsorbed by the body, and subsequent loss of some or all of the breast volume over the time, remains pervasive, adding to the reluctance of consumers to opt for autologous fat grafting procedures.
  • Concerns pertaining to the ability of certain fat cells to stimulate cell growth continue to restrict doctors from practicing the autologous fat grafting technique. As fat injected into the breast area may cause a spike in dormant breast cancer cells, manufactures continue to struggle for better revenues.
  • Some of the fat injected into the breast area may result in necrosis, preceded by pain, puss formation, and related symptoms. Such risks associated with fat grafting procedures will continue to create a major barrier, facing the thriving autologous fat grafting market.

Competition Landscape

The four leading companies that account for the consolidation of the competition landscape of autologous fat grafting market, continue to represent a whopping 80% share in the revenues. Allergan, MicroAire, Alma Lasers, and Human Med are expected to primarily maintain their strategic focus on partnerships and acquisitions with smaller yet active players. The latter are typically specialized in the development of meniscus repair systems for treating meniscal scars. With this, leading companies operating in autologous fat grafting industry, are eyeing feasibility of entry in the meniscal scars treatment landscape. Increasing strategic tie-ups among manufacturers of systems & accessories, and recognized research institutions, aim to ensure sufficient device supply and superior post-sales service.

Manufacturers in the autologous fat grafting market are also investing efforts in introducing innovative products, to enhance their market shares. For instance, in 2019, Alma Lasers (Sisram Medical) announced the availability of BeautiFill as the novel laser-based technique for fat harvesting, while leveraging autologous fat to restore the volume to body or face. As cellular therapies are increasingly being perceived as mainstream therapeutic option, there has been a surge in demand for adipose derived stem cells (ADSC), which is potentially applicable in tissue engineering and regeneration. Additionally, a growing focus of leading players on introducing advanced systems & accessories is likely to extend applicability of their offerings, leveraging untapped opportunities in the autologous fat grafting market.

Like it? Share it!


About the Author

Joined: December 18th, 2017
Articles Posted: 13,297

More by this author